It’s all about understanding “half-life”, how the drug spends. If CD12 dosage hadn’t been capped a lot of those over 65 patients would be alive today. Geez, let the doctors practice real medicine and treat their patients. Obviously the case study of that patient recovering with 4 doses after 84 days on ECMO made them look carefully at the CD12 data again.
Yep, plus it is becoming clear that Leronlimab is the best therapeutic. It is clearly superior to those by HGEN and RLFTF, and the market is starting to recognize this despite the games, agendas and other BS. CYDY LONG!